US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

ArriVent BioPharma

19.53

+0.91004.89%

Post-market: 19.530.00000.00%19:23 EDT

Volume:274.80K

Turnover:5.31M

Market Cap:792.31M

PE:-4.86

High:19.86

Open:18.74

Low:18.47

Close:18.62

52wk High:36.37

52wk Low:15.47

Shares:40.57M

Float Shares:18.29M

Volume Ratio:0.58

T/O Rate:1.50%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-4.0162

EPS(LYR):-2.5577

ROE:-50.06%

ROA:-23.41%

PB:3.17

PE(LYR):-7.64

Loading ...

Overview Company News Filings

BUZZ-ArriVent BioPharma drops after $75 mln equity raise

ArriVent BioPharma Plans $75 Million Public Offering

MT Newswires Live

BRIEF-Arrivent Proposes $75 Million Public Offering of Common Stock and Pre-Funded Warrants

Wall Street Analysts Are Bullish on Top NA Picks

ArriVent BioPharma Initiated at Buy by Clear Street

ArriVent Biopharma initiated with a Buy at Clear Street

ArriVent BioPharma Price Target Maintained With a $45.00/Share by Guggenheim

Analysts Offer Insights on NA Companies: Reddit Inc Class A (RDDT), ArriVent BioPharma, Inc. (AVBP) and Fractyl Health, Inc. (GUTS)

ArriVent BioPharma Reports Positive Phase 1b Study Results

ArriVent BioPharma’s Firmonertinib Shows Promise in NSCLC Treatment with Strong Phase 1b Results and Strategic Phase 3 Plans

ArriVent BioPharma Says Interim Results From Lung Cancer Drug Trial Showed 16 Months Median Progression-Free Survival

MT Newswires Live

ArriVent Biopharma Announces Positive Interim Data from Phase 1b Firmonertinib Trial in EGFR PACC Mutant NSCLC and Plans Global Pivotal Study

ArriVent Biopharma Inc. Conducted Annual Stockholders Meeting

Positive Outlook for ArriVent BioPharma Amid Strong Stock Momentum and Anticipated Trial Success

Optimistic Outlook for ArriVent BioPharma, Inc. Amid Promising Developments and Market Support

Promising Outlook for ArriVent BioPharma: Buy Rating Justified by Upcoming EGFR PACC Mutant NSCLC Program Updates

ArriVent BioPharma Is Maintained at Buy by HC Wainwright & Co.

Press Release: ArriVent BioPharma Reports First Quarter 2025 Financial Results

Arrivent Biopharma Inc expected to post a loss of 66 cents a share - Earnings Preview

Press Release: ArriVent BioPharma Appoints Merdad Parsey, M.D., Ph.D. to its Board of Directors

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/AVBP/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"AVBP","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"AVBP\",,,,,undefined,":{"symbol":"AVBP","market":"US","secType":"STK","nameCN":"ArriVent BioPharma","latestPrice":19.53,"timestamp":1755288000000,"preClose":18.62,"halted":0,"volume":274802,"hourTrading":{"tag":"盘后","latestPrice":19.53,"preClose":19.53,"latestTime":"19:23 EDT","volume":2349,"amount":45876.54,"timestamp":1755300211489},"delay":0,"floatShares":18293400,"shares":40568944,"eps":-4.016159,"marketStatus":"Market Closed","change":0.91,"latestTime":"08-15 16:00:00 EDT","open":18.74,"high":19.855,"low":18.4684,"amount":5305962.20462,"amplitude":0.074468,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-4.016159,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1755504000000},"marketStatusCode":7,"adr":0,"listingDate":1706245200000,"exchange":"NASDAQ","adjPreClose":18.62,"preHourTrading":{"tag":"盘前","latestPrice":18.62,"preClose":18.62,"latestTime":"08:45 EDT","volume":25850,"amount":481327,"timestamp":1755261950467},"postHourTrading":{"tag":"盘后","latestPrice":19.53,"preClose":19.53,"latestTime":"19:23 EDT","volume":2349,"amount":45876.54,"timestamp":1755300211489},"volumeRatio":0.5815462898282058,"impliedVol":0.6794,"impliedVolPercentile":0.8427},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"AVBP\",,,,,undefined,":{"symbol":"AVBP","floatShares":18293400,"roa":"-23.41%","roe":"-50.06%","lyrEps":-2.557665,"volumeRatio":0.5815462898282058,"shares":40568944,"dividePrice":0,"high":19.855,"amplitude":0.074468,"preClose":18.62,"low":18.4684,"week52Low":15.47,"pbRate":"3.17","week52High":36.37,"institutionHeld":0,"latestPrice":19.53,"eps":-4.016159,"divideRate":0,"volume":274802,"delay":0,"ttmEps":-4.016159,"open":18.74,"prevYearClose":26.64,"prevWeekClose":17.99,"prevMonthClose":19.51,"prevQuarterClose":21.77,"fiveDayClose":17.99,"twentyDayClose":22.05,"sixtyDayClose":20.86},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/AVBP\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-08-11","symbol":"AVBP","fiscalQuarterEnding":"2025/06","expectedEps":-0.7,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1754884800000,"reportTimeType":"pre","actualEps":-0.9},{"market":"US","date":"2025-05-12","symbol":"AVBP","fiscalQuarterEnding":"2025/03","expectedEps":-0.66,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1747022400000,"reportTimeType":"pre","actualEps":-1.9},{"market":"US","date":"2025-03-03","symbol":"AVBP","fiscalQuarterEnding":"2024/12","expectedEps":-0.78,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1740978000000,"reportTimeType":"pre","actualEps":-0.6},{"market":"US","date":"2024-11-14","symbol":"AVBP","fiscalQuarterEnding":"2024/09","expectedEps":-0.82,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1731560400000,"reportTimeType":"pre","actualEps":-0.61}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"AVBP\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"AVBP\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.4,"buy":0.6,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.6,"analysts":10,"updateTime":1753502400000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/AVBP\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"AVBP","date":"2025-08-15","current":-5.522288,"percent":0.954178,"low":-15.980041,"twenty":-11.663891,"median":-9.64689,"eighty":-7.464633,"high":-4.80343,"avg":-9.536289,"sd":2.432263,"marketCap":755393737},"quantilePoints":[{"date":"2024-01-26","current":-15.452095,"twenty":-15.452095,"median":-15.452095,"eighty":-15.452095,"marketCap":905214654},{"date":"2024-02-02","current":-11.990156,"twenty":-12.001066,"median":-11.872873,"eighty":-10.91006,"marketCap":702407320},{"date":"2024-02-09","current":-12.548731,"twenty":-12.548731,"median":-12.001066,"eighty":-11.75559,"marketCap":735129780},{"date":"2024-02-16","current":-12.588659,"twenty":-12.548731,"median":-12.126596,"eighty":-11.919241,"marketCap":737468829},{"date":"2024-02-23","current":-11.219707,"twenty":-12.556717,"median":-11.998256,"eighty":-11.67237,"marketCap":657272853},{"date":"2024-03-01","current":-12.286349,"twenty":-12.548731,"median":-11.990156,"eighty":-11.204877,"marketCap":719758884},{"date":"2024-03-08","current":-11.464977,"twenty":-12.548731,"median":-11.964074,"eighty":-11.315533,"marketCap":671641299},{"date":"2024-03-15","current":-10.59227,"twenty":-12.5031,"median":-11.767288,"eighty":-11.121598,"marketCap":620516364},{"date":"2024-03-22","current":-10.386927,"twenty":-12.327418,"median":-11.658912,"eighty":-10.920492,"marketCap":608486967},{"date":"2024-03-28","current":-10.267144,"twenty":-12.279504,"median":-11.507757,"eighty":-10.718898,"marketCap":601469820},{"date":"2024-04-05","current":-8.84046,"twenty":-12.261251,"median":-11.265338,"eighty":-10.410884,"marketCap":612935625},{"date":"2024-04-12","current":-8.536116,"twenty":-12.10149,"median":-11.165519,"eighty":-9.961411,"marketCap":591834562},{"date":"2024-04-19","current":-7.487821,"twenty":-11.997694,"median":-11.025772,"eighty":-8.805678,"marketCap":519153125},{"date":"2024-04-26","current":-7.507145,"twenty":-11.992272,"median":-10.91658,"eighty":-8.501334,"marketCap":520492875},{"date":"2024-05-03","current":-8.115832,"twenty":-11.986485,"median":-10.803317,"eighty":-8.191193,"marketCap":562695000},{"date":"2024-05-10","current":-8.079495,"twenty":-11.960082,"median":-10.543786,"eighty":-8.115832,"marketCap":602552562},{"date":"2024-05-17","current":-9.049573,"twenty":-11.929189,"median":-10.386927,"eighty":-8.101297,"marketCap":674899062},{"date":"2024-05-24","current":-8.479203,"twenty":-11.828069,"median":-10.210104,"eighty":-8.115832,"marketCap":632362000},{"date":"2024-05-31","current":-8.739687,"twenty":-11.762609,"median":-9.361752,"eighty":-8.133223,"marketCap":651788375},{"date":"2024-06-07","current":-8.241175,"twenty":-11.7192,"median":-8.959751,"eighty":-8.180566,"marketCap":614610312},{"date":"2024-06-14","current":-8.456747,"twenty":-11.662334,"median":-8.912923,"eighty":-8.216398,"marketCap":630687312},{"date":"2024-06-21","current":-7.455231,"twenty":-11.653208,"median":-8.84046,"eighty":-8.15931,"marketCap":555996250},{"date":"2024-06-28","current":-7.81452,"twenty":-11.61214,"median":-8.79358,"eighty":-8.133223,"marketCap":582791250},{"date":"2024-07-05","current":-8.205246,"twenty":-11.533425,"median":-8.753505,"eighty":-8.152944,"marketCap":611930812},{"date":"2024-07-12","current":-8.268121,"twenty":-11.43988,"median":-8.706383,"eighty":-8.152944,"marketCap":616619937},{"date":"2024-07-15","current":-8.259139,"twenty":-11.414782,"median":-8.695535,"eighty":-8.154535,"marketCap":615950062},{"date":"2024-08-02","current":-9.655872,"twenty":-11.389685,"median":-8.706383,"eighty":-8.156127,"marketCap":720115625},{"date":"2024-08-09","current":-10.262171,"twenty":-11.294999,"median":-8.753505,"eighty":-8.186872,"marketCap":765332187},{"date":"2024-08-16","current":-10.701201,"twenty":-11.237959,"median":-8.81702,"eighty":-8.205246,"marketCap":801359406},{"date":"2024-08-23","current":-10.705686,"twenty":-11.199173,"median":-8.912923,"eighty":-8.209568,"marketCap":801695265},{"date":"2024-08-30","current":-12.010819,"twenty":-11.389685,"median":-8.993434,"eighty":-8.224295,"marketCap":899430214},{"date":"2024-09-06","current":-11.93009,"twenty":-11.657877,"median":-9.253918,"eighty":-8.235785,"marketCap":893384753},{"date":"2024-09-13","current":-10.669806,"twenty":-11.694732,"median":-9.655872,"eighty":-8.248361,"marketCap":799008394},{"date":"2024-09-20","current":-10.85369,"twenty":-11.663166,"median":-9.763659,"eighty":-8.262732,"marketCap":812778610},{"date":"2024-09-27","current":-10.544226,"twenty":-11.657877,"median":-10.060071,"eighty":-8.269917,"marketCap":789604344},{"date":"2024-10-04","current":-11.49056,"twenty":-11.61214,"median":-10.208101,"eighty":-8.279798,"marketCap":860470578},{"date":"2024-10-11","current":-12.463804,"twenty":-11.739278,"median":-10.315491,"eighty":-8.299559,"marketCap":933351966},{"date":"2024-10-18","current":-13.002004,"twenty":-11.938503,"median":-10.371883,"eighty":-8.317243,"marketCap":973655038},{"date":"2024-10-25","current":-13.912458,"twenty":-11.99333,"median":-10.426855,"eighty":-8.325491,"marketCap":1041834400},{"date":"2024-10-31","current":-14.114283,"twenty":-12.114871,"median":-10.539741,"eighty":-8.328911,"marketCap":1056948052},{"date":"2024-11-08","current":-15.980041,"twenty":-12.249611,"median":-10.573379,"eighty":-8.330997,"marketCap":1196665367},{"date":"2024-11-15","current":-11.674764,"twenty":-12.282511,"median":-10.59227,"eighty":-8.332793,"marketCap":946216280},{"date":"2024-11-22","current":-11.05527,"twenty":-12.272349,"median":-10.669806,"eighty":-8.342492,"marketCap":896007510},{"date":"2024-11-29","current":-12.456408,"twenty":-12.274941,"median":-10.685503,"eighty":-8.352544,"marketCap":1009566943},{"date":"2024-12-06","current":-11.870175,"twenty":-12.284404,"median":-10.712096,"eighty":-8.353452,"marketCap":962053946},{"date":"2024-12-13","current":-10.760075,"twenty":-12.274941,"median":-10.748293,"eighty":-8.371867,"marketCap":872082526},{"date":"2024-12-20","current":-10.664448,"twenty":-12.261979,"median":-10.759506,"eighty":-8.380399,"marketCap":864332179},{"date":"2024-12-27","current":-11.46688,"twenty":-12.254096,"median":-10.803317,"eighty":-8.380399,"marketCap":929367700},{"date":"2025-01-03","current":-11.421146,"twenty":-12.244582,"median":-10.85369,"eighty":-8.380399,"marketCap":925661012},{"date":"2025-01-10","current":-11.167527,"twenty":-12.234172,"median":-10.860965,"eighty":-8.382195,"marketCap":905105744},{"date":"2025-01-17","current":-10.177999,"twenty":-12.217129,"median":-10.850538,"eighty":-8.390279,"marketCap":824906501},{"date":"2025-01-24","current":-11.329677,"twenty":-12.196013,"median":-10.850538,"eighty":-8.405549,"marketCap":918247637},{"date":"2025-01-31","current":-12.09469,"twenty":-12.164539,"median":-10.860965,"eighty":-8.437266,"marketCap":980250413},{"date":"2025-02-07","current":-11.383727,"twenty":-12.161213,"median":-10.897572,"eighty":-8.450678,"marketCap":922628268},{"date":"2025-02-14","current":-11.16337,"twenty":-12.157147,"median":-10.9231,"eighty":-8.461238,"marketCap":904768772},{"date":"2025-02-21","current":-11.387884,"twenty":-12.140884,"median":-10.92545,"eighty":-8.479203,"marketCap":922965239},{"date":"2025-02-28","current":-9.8537,"twenty":-12.107163,"median":-10.91658,"eighty":-8.519623,"marketCap":798622715},{"date":"2025-03-07","current":-9.217439,"twenty":-12.09469,"median":-10.885085,"eighty":-8.536116,"marketCap":741893256},{"date":"2025-03-14","current":-9.192082,"twenty":-12.065586,"median":-10.857328,"eighty":-8.618427,"marketCap":739852284},{"date":"2025-03-21","current":-8.258082,"twenty":-12.010819,"median":-10.847386,"eighty":-8.519623,"marketCap":664676489},{"date":"2025-03-28","current":-7.848136,"twenty":-12.001066,"median":-10.781696,"eighty":-8.449161,"marketCap":631680778},{"date":"2025-04-04","current":-7.159258,"twenty":-11.995446,"median":-10.737081,"eighty":-8.380399,"marketCap":576234377},{"date":"2025-04-11","current":-7.125448,"twenty":-11.990156,"median":-10.711139,"eighty":-8.353452,"marketCap":573513081},{"date":"2025-04-17","current":-7.564978,"twenty":-11.988746,"median":-10.703443,"eighty":-8.330997,"marketCap":608889926},{"date":"2025-04-25","current":-8.94696,"twenty":-11.984909,"median":-10.669806,"eighty":-8.330476,"marketCap":720122890},{"date":"2025-05-02","current":-8.908923,"twenty":-11.976101,"median":-10.6604,"eighty":-8.330997,"marketCap":717061432},{"date":"2025-05-09","current":-8.353948,"twenty":-11.95416,"median":-10.580862,"eighty":-8.330997,"marketCap":672392561},{"date":"2025-05-16","current":-5.164444,"twenty":-11.945123,"median":-10.566696,"eighty":-8.323142,"marketCap":658249673},{"date":"2025-05-23","current":-5.537551,"twenty":-11.932894,"median":-10.539741,"eighty":-8.281274,"marketCap":705805133},{"date":"2025-05-30","current":-5.636867,"twenty":-11.923581,"median":-10.506711,"eighty":-8.258716,"marketCap":718463781},{"date":"2025-06-06","current":-6.29987,"twenty":-11.889801,"median":-10.45834,"eighty":-8.241176,"marketCap":802968806},{"date":"2025-06-13","current":-6.342817,"twenty":-11.86768,"median":-10.37894,"eighty":-8.205246,"marketCap":808442816},{"date":"2025-06-20","current":-6.681029,"twenty":-11.831093,"median":-10.360937,"eighty":-8.13004,"marketCap":851550643},{"date":"2025-06-27","current":-6.122711,"twenty":-11.774139,"median":-10.336565,"eighty":-8.056606,"marketCap":780388516},{"date":"2025-07-03","current":-5.951741,"twenty":-11.764948,"median":-10.291317,"eighty":-8.012114,"marketCap":758596999},{"date":"2025-07-11","current":-6.3128,"twenty":-11.752729,"median":-10.177999,"eighty":-7.877518,"marketCap":804616846},{"date":"2025-07-18","current":-6.510523,"twenty":-11.737545,"median":-10.15098,"eighty":-7.814365,"marketCap":829818191},{"date":"2025-07-25","current":-6.146598,"twenty":-11.721024,"median":-10.060071,"eighty":-7.74746,"marketCap":783433107},{"date":"2025-08-01","current":-5.590682,"twenty":-11.706801,"median":-9.819907,"eighty":-7.667253,"marketCap":712577152},{"date":"2025-08-08","current":-5.312724,"twenty":-11.672734,"median":-9.759167,"eighty":-7.57343,"marketCap":677149175},{"date":"2025-08-15","current":-5.522288,"twenty":-11.663891,"median":-9.64689,"eighty":-7.464633,"marketCap":755393737}],"updateTime":1755422879484},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"AVBP\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2548889959","title":"BUZZ-ArriVent BioPharma drops after $75 mln equity raise","url":"https://stock-news.laohu8.com/highlight/detail?id=2548889959","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2548889959?lang=en_us&edition=fundamental","pubTime":"2025-07-02 19:25","pubTimestamp":1751455515,"startTime":"0","endTime":"0","summary":"BUZZ-ArriVent BioPharma drops after $75 mln equity raise** ArriVent BioPharma's AVBP.O shares down 4.3% premarket at $20 after overnight follow-on priced** Newtown Square, Pennsylvania-based late Tues announced ~3.8 mln shares, including pre-funded warrants to buy ~1.4 mln shares, for $75 mln gross proceeds** Offering price of $19.50 is 6.7% discount to stock's last sale** Co to use net proceeds to support activities for lead candidate, firmonertinib, its treatment for non-small cell lung cancer, and other pipeline programs, among other general purposes** Goldman Sachs, Citigroup and Guggenheim are jt bookrunners for offering** ArriVent has ~34.2 mln shares outstanding for ~$715 mln market cap** AVBP shares on Tues fell 4% to $20.89, stretching YTD loss to ~22%** All 8 analysts are bullish on AVBP with avg rating of \"strong buy\" and median PT is $40, latest LSEG data reflects","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250702:nL6N3SZ0G7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4552","LU1894683348.USD","LU2417539215.USD","LU0130517989.USD","LU0320765646.SGD","BK4139","IE0004091025.USD","BK4585","LU2125154935.USD","LU1366192091.USD","LU2236285917.USD","LU2237443622.USD","BK4516","BK4550","LU1868836591.USD","LU0098860793.USD","BK4588","LU1791807156.HKD","LU0130102774.USD","BK4559","LU2237443465.HKD","LU0170899867.USD","LU1868836757.USD","LU0096364046.USD","LU0742534661.SGD","AVBP","IE0034235188.USD","LU0648001328.SGD","LU2237443382.USD","LU2471134523.USD","LU0106831901.USD","LU2360032135.SGD","LU0310800965.SGD","LU0061475181.USD","LU2750360641.GBP","LU0980610538.SGD","IE00BSNM7G36.USD","LU0162691827.USD","LU0052756011.USD","LU2237438978.USD","LU0251131958.USD","LU0477156953.USD","LU2471134796.USD","LU1267930227.SGD","BK4533","LU1894683264.USD","LU1868837136.USD","LU1201861249.SGD","LU2237443549.SGD","BK4127"],"gpt_icon":0},{"id":"2548865887","title":"ArriVent BioPharma Plans $75 Million Public Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2548865887","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2548865887?lang=en_us&edition=fundamental","pubTime":"2025-07-02 04:24","pubTimestamp":1751401496,"startTime":"0","endTime":"0","summary":"ArriVent BioPharma  said late Tuesday it plans a $75 million public offering of common shares and pre-funded warrants.The company said it will offer underwriters a 30-day overallotment option to buy up to an additional 15% of the total offering size.ArriVent will use the net proceeds to advance activities related to its firmonertinib drug to treat non-squamous non-small cell lung cancer, as well as for general corporate purposes, the company said.Shares of the company fell 5.7% during after-hours activity.Price: 19.70, Change: -1.19, Percent Change: -5.70","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","AVBP"],"gpt_icon":0},{"id":"2548444882","title":"BRIEF-Arrivent Proposes $75 Million Public Offering of Common Stock and Pre-Funded Warrants","url":"https://stock-news.laohu8.com/highlight/detail?id=2548444882","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2548444882?lang=en_us&edition=fundamental","pubTime":"2025-07-02 04:11","pubTimestamp":1751400701,"startTime":"0","endTime":"0","summary":"BRIEF-Arrivent Proposes $75 Million Public Offering of Common Stock and Pre-Funded WarrantsJuly 1 (Reuters) - Arrivent Biopharma Inc AVBP.O:ARRIVENT ANNOUNCES PROPOSED $75 MILLION PUBLIC OFFERING OF C","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250701:nTUA2QT3PW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AVBP","BK4139"],"gpt_icon":0},{"id":"2547720098","title":"Wall Street Analysts Are Bullish on Top NA Picks","url":"https://stock-news.laohu8.com/highlight/detail?id=2547720098","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2547720098?lang=en_us&edition=fundamental","pubTime":"2025-06-30 18:40","pubTimestamp":1751280012,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the NA sector as 2 analysts just weighed in on ArriVent BioPharma, Inc. (AVBP – Research Report) and Waysta...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/wall-street-analysts-are-bullish-on-top-na-picks-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/wall-street-analysts-are-bullish-on-top-na-picks-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","AVBP","BK4141"],"gpt_icon":0},{"id":"2546401872","title":"ArriVent BioPharma Initiated at Buy by Clear Street","url":"https://stock-news.laohu8.com/highlight/detail?id=2546401872","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2546401872?lang=en_us&edition=fundamental","pubTime":"2025-06-26 01:37","pubTimestamp":1750873020,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/AVBP/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  June 25, 2025 13:37 ET (17:37 GMT)","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AVBP","BK4139"],"gpt_icon":0},{"id":"2546253263","title":"ArriVent Biopharma initiated with a Buy at Clear Street","url":"https://stock-news.laohu8.com/highlight/detail?id=2546253263","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2546253263?lang=en_us&edition=fundamental","pubTime":"2025-06-25 04:30","pubTimestamp":1750797012,"startTime":"0","endTime":"0","summary":"Clear Street analyst Kaveri Pohlman initiated coverage of ArriVent Biopharma (AVBP) with a Buy rating and $32 price target Firmonertinib, ArriVent’...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/arrivent-biopharma-initiated-with-a-buy-at-clear-street-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/arrivent-biopharma-initiated-with-a-buy-at-clear-street-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","AVBP"],"gpt_icon":0},{"id":"2545287189","title":"ArriVent BioPharma Price Target Maintained With a $45.00/Share by Guggenheim","url":"https://stock-news.laohu8.com/highlight/detail?id=2545287189","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2545287189?lang=en_us&edition=fundamental","pubTime":"2025-06-24 20:48","pubTimestamp":1750769280,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/AVBP/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  June 24, 2025 08:48 ET (12:48 GMT)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AVBP"],"gpt_icon":0},{"id":"2545284160","title":"Analysts Offer Insights on NA Companies: Reddit Inc Class A (RDDT), ArriVent BioPharma, Inc. (AVBP) and Fractyl Health, Inc. (GUTS)","url":"https://stock-news.laohu8.com/highlight/detail?id=2545284160","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2545284160?lang=en_us&edition=fundamental","pubTime":"2025-06-24 19:50","pubTimestamp":1750765840,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the NA sector as 3 analysts just weighed in on Reddit Inc Class A (RDDT – Research Report), ArriVent BioPha...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-na-companies-reddit-inc-class-a-rddt-arrivent-biopharma-inc-avbp-and-fractyl-health-inc-guts-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-na-companies-reddit-inc-class-a-rddt-arrivent-biopharma-inc-avbp-and-fractyl-health-inc-guts-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU1861220033.SGD","BK4082","BK4547","BK4077","LU1861215975.USD","NA","RDDT","BK4141","GUTS","LU2360107168.USD","LU2290526834.HKD","AVBP","BK4139"],"gpt_icon":0},{"id":"2545694444","title":"ArriVent BioPharma Reports Positive Phase 1b Study Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2545694444","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2545694444?lang=en_us&edition=fundamental","pubTime":"2025-06-24 02:27","pubTimestamp":1750703259,"startTime":"0","endTime":"0","summary":"An announcement from ArriVent BioPharma, Inc. ( ($AVBP) ) is now available. On June 23, 2025, ArriVent BioPharma announced positive interim data fr...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/arrivent-biopharma-reports-positive-phase-1b-study-results?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/arrivent-biopharma-reports-positive-phase-1b-study-results?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","AVBP"],"gpt_icon":0},{"id":"2545611444","title":"ArriVent BioPharma’s Firmonertinib Shows Promise in NSCLC Treatment with Strong Phase 1b Results and Strategic Phase 3 Plans","url":"https://stock-news.laohu8.com/highlight/detail?id=2545611444","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2545611444?lang=en_us&edition=fundamental","pubTime":"2025-06-24 02:25","pubTimestamp":1750703116,"startTime":"0","endTime":"0","summary":"In a report released today, Sam Slutsky from LifeSci Capital maintained a Buy rating on ArriVent BioPharma, Inc. (AVBP – Research Report), with a p...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/arrivent-biopharmas-firmonertinib-shows-promise-in-nsclc-treatment-with-strong-phase-1b-results-and-strategic-phase-3-plans-ratings?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/arrivent-biopharmas-firmonertinib-shows-promise-in-nsclc-treatment-with-strong-phase-1b-results-and-strategic-phase-3-plans-ratings?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","AVBP"],"gpt_icon":0},{"id":"2545119684","title":"ArriVent BioPharma Says Interim Results From Lung Cancer Drug Trial Showed 16 Months Median Progression-Free Survival","url":"https://stock-news.laohu8.com/highlight/detail?id=2545119684","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2545119684?lang=en_us&edition=fundamental","pubTime":"2025-06-23 20:15","pubTimestamp":1750680958,"startTime":"0","endTime":"0","summary":"ArriVent BioPharma  said Monday that interim results from a global phase 1b study of firmonertinib monotherapy showed 16 months median progression-free survival for patients treated with firmonertinib 240 mg in non-small cell lung cancer with epidermal growth factor receptor PACC mutations.A majority of patients treated at 240 mg dose remain on trial following a year, with 14.6 months median duration of response, the company said, adding that the potential treatment showed a 68.2% confirmed overall response rate at the dose level.The trial data demonstrated strong central nervous system activity, with 41% confirmed complete response and 53% confirmed overall response in CNS evaluable disease patients, ArriVent BioPharma said.The company also said enrollment in a global phase 3 trial will likely begin in H2.ArriVent BioPharma's shares were up 5.1% in recent Monday premarket activity.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","AVBP"],"gpt_icon":0},{"id":"2545415784","title":"ArriVent Biopharma Announces Positive Interim Data from Phase 1b Firmonertinib Trial in EGFR PACC Mutant NSCLC and Plans Global Pivotal Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2545415784","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2545415784?lang=en_us&edition=fundamental","pubTime":"2025-06-23 19:07","pubTimestamp":1750676869,"startTime":"0","endTime":"0","summary":"ArriVent Biopharma Announces Positive Interim Data from Phase 1b Firmonertinib Trial in EGFR PACC Mutant NSCLC and Plans Global Pivotal Study. ArriVent Biopharma Inc., a clinical-stage biopharmaceutical company, announced positive interim data from their global Phase 1b FURTHER trial of firmonertinib monotherapy for patients with non-small cell lung cancer  harboring EGFR PACC mutations. The data revealed a median progression free survival of 16.0 months, with robust CNS activity observed in the trial. The company plans to advance to a pivotal global Phase 3 study, named ALPACCA, with the enrollment of the first patient expected in the second half of 2025. The results were presented during a virtual webinar held on June 23, 2025.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted a","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250623:nNDL1Wfc5n:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AVBP","BK4139"],"gpt_icon":0},{"id":"2545170292","title":"ArriVent Biopharma Inc. Conducted Annual Stockholders Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2545170292","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2545170292?lang=en_us&edition=fundamental","pubTime":"2025-06-21 04:15","pubTimestamp":1750450512,"startTime":"0","endTime":"0","summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ArriVent Biopharma Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 20, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250620:nNDL1kPGYq:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","AVBP"],"gpt_icon":0},{"id":"2544198892","title":"Positive Outlook for ArriVent BioPharma Amid Strong Stock Momentum and Anticipated Trial Success","url":"https://stock-news.laohu8.com/highlight/detail?id=2544198892","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2544198892?lang=en_us&edition=fundamental","pubTime":"2025-06-17 04:05","pubTimestamp":1750104312,"startTime":"0","endTime":"0","summary":"Soumit Roy, an analyst from JonesTrading, maintained the Buy rating on ArriVent BioPharma, Inc. (AVBP – Research Report). The associated price targ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/positive-outlook-for-arrivent-biopharma-amid-strong-stock-momentum-and-anticipated-trial-success-ratings?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/positive-outlook-for-arrivent-biopharma-amid-strong-stock-momentum-and-anticipated-trial-success-ratings?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["AVBP","BK4139"],"gpt_icon":0},{"id":"2542933521","title":"Optimistic Outlook for ArriVent BioPharma, Inc. Amid Promising Developments and Market Support","url":"https://stock-news.laohu8.com/highlight/detail?id=2542933521","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2542933521?lang=en_us&edition=fundamental","pubTime":"2025-06-09 23:15","pubTimestamp":1749482120,"startTime":"0","endTime":"0","summary":"Analyst Soumit Roy of JonesTrading maintained a Buy rating on ArriVent BioPharma, Inc. (AVBP – Research Report), retaining the price target of $40....","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/optimistic-outlook-for-arrivent-biopharma-inc-amid-promising-developments-and-market-support-ratings?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/optimistic-outlook-for-arrivent-biopharma-inc-amid-promising-developments-and-market-support-ratings?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["AVBP","BK4139"],"gpt_icon":0},{"id":"2539694267","title":"Promising Outlook for ArriVent BioPharma: Buy Rating Justified by Upcoming EGFR PACC Mutant NSCLC Program Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2539694267","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2539694267?lang=en_us&edition=fundamental","pubTime":"2025-05-30 00:55","pubTimestamp":1748537719,"startTime":"0","endTime":"0","summary":"Analyst Soumit Roy from JonesTrading maintained a Buy rating on ArriVent BioPharma, Inc. (AVBP – Research Report) and keeping the price target at $...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/promising-outlook-for-arrivent-biopharma-buy-rating-justified-by-upcoming-egfr-pacc-mutant-nsclc-program-updates?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/promising-outlook-for-arrivent-biopharma-buy-rating-justified-by-upcoming-egfr-pacc-mutant-nsclc-program-updates?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PACC","AVBP"],"gpt_icon":0},{"id":"2535056970","title":"ArriVent BioPharma Is Maintained at Buy by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2535056970","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535056970?lang=en_us&edition=fundamental","pubTime":"2025-05-15 01:37","pubTimestamp":1747244220,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/AVBP/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  May 14, 2025 13:37 ET (17:37 GMT)","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AVBP"],"gpt_icon":0},{"id":"2534722462","title":"Press Release: ArriVent BioPharma Reports First Quarter 2025 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2534722462","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2534722462?lang=en_us&edition=fundamental","pubTime":"2025-05-12 20:00","pubTimestamp":1747051200,"startTime":"0","endTime":"0","summary":"-- Completed enrollment in global pivotal Phase 3 study for firmonertinib. monotherapy in first-line NSCLC harboring EGFR exon 20 insertion. -- Planned update for development of firmonertinib in first-line NSCLC PACC. -- First IND for ARR-217 , an antibody drug conjugate . -- Cash, cash equivalents and marketable securities of $205.5 million as of. \"We continued our strong execution across our oncology-focused pipeline and are preparing for several near-term milestones. Importantly, our late-stage firmonertinib program continues to show differentiated potential to address unmet needs across EGFR-mutant non-small cell lung cancer ,\" said Bing Yao, Chairman and Chief Executive Officer of ArriVent. \"ARR-217 , our recently acquired antibody drug conjugate  targeting the gastrointestinal marker CDH17 with best-in-class potential, is expected to be the first ADC from our pipeline to enter the clinic.\". -- Completed enrollment for pivotal trial. During the first quarter of 2025,we completed e","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4231","BK4195","BK4080","PACC","BK4139","AVBP","PFS","ADC","BK4211"],"gpt_icon":0},{"id":"2533831725","title":"Arrivent Biopharma Inc  expected to post a loss of 66 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2533831725","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533831725?lang=en_us&edition=fundamental","pubTime":"2025-05-05 19:33","pubTimestamp":1746444791,"startTime":"0","endTime":"0","summary":"Arrivent Biopharma Inc  expected to post a loss of66cents a share - Earnings Preview Arrivent Biopharma Inc AVBP.OQ AVBP.O is expected to show no change in quarterly revenue when it reports  results o","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250505:nL8N3RD0OF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AVBP"],"gpt_icon":0},{"id":"2530039724","title":"Press Release: ArriVent BioPharma Appoints Merdad Parsey, M.D., Ph.D. to its Board of Directors","url":"https://stock-news.laohu8.com/highlight/detail?id=2530039724","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530039724?lang=en_us&edition=fundamental","pubTime":"2025-04-28 20:00","pubTimestamp":1745841600,"startTime":"0","endTime":"0","summary":"NEWTOWN SQUARE, Pa., April 28, 2025  -- ArriVent BioPharma, Inc.  , a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics, today announced the appointment of Merdad Parsey, M.D., Ph.D. to its Board of Directors. Dr. Parsey brings decades of executive experience leading global clinical development in the biopharmaceutical industry, most recently serving as Chief Medical Officer and Executive Vice President of Gilead Sciences, Inc.\"Dr. Parsey is a seasoned executive who has driven therapeutic innovation and strategic growth at prominent pharmaceutical and biotech companies across a broad array of therapeutic areas,\" said Bing Yao, Chairman and Chief Executive Officer of ArriVent. \"We are thrilled to have him join our Board of Directors at this important time and leverage his experience as firmonertinib progresses towards registration and we advance our antibody drug conjugate  pipeline.\". ArriVent is a clinical-stage biopha","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ADC","BK4231","AVBP","BK4080"],"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":2,"totalSize":48,"code":"91000000","status":"200"}]}}